SARS-CoV-2 Zeta variant
Variant of SARS-CoV-2
The SARS-CoV-2 Zeta variant, also known as lineage P.2, is a variant of the virus SARS-CoV-2, which causes the disease COVID-19. This variant was first identified in Brazil and has been associated with increased transmissibility and potential impacts on vaccine efficacy.
Discovery and Spread
The Zeta variant was first detected in Brazil in late 2020. It emerged in the context of widespread transmission of SARS-CoV-2 in the country, which provided opportunities for the virus to mutate and evolve. The variant was identified through genomic sequencing efforts aimed at tracking the evolution of the virus.
Genetic Characteristics
The Zeta variant is characterized by specific mutations in the spike protein of the virus, which is the primary target for COVID-19 vaccines. These mutations include E484K, which is known to affect the virus's ability to evade the immune response generated by previous infection or vaccination.
Impact on Public Health
The emergence of the Zeta variant raised concerns about its potential impact on the effectiveness of existing vaccines and the risk of reinfection. Studies have suggested that the E484K mutation may reduce the neutralizing activity of antibodies, potentially leading to decreased vaccine efficacy. However, vaccines have still been shown to provide significant protection against severe disease and hospitalization.
Response and Mitigation
In response to the spread of the Zeta variant, public health authorities in Brazil and other countries have intensified efforts to monitor and control its transmission. This includes increased genomic surveillance, public health measures such as social distancing and mask-wearing, and the acceleration of vaccination campaigns.
Current Status
As of 2023, the Zeta variant is no longer classified as a variant of concern by the World Health Organization (WHO), but it remains a variant of interest due to its mutations and potential impact on public health. Ongoing research continues to monitor the variant's spread and its implications for vaccine strategies.
Related pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD